eGFR signaling in colorectal cancer: a clinical perspective

摘要: Colorectal cancer (CRC) remains a formidable health burden worldwide, with up to 50% of patients developing metastases during the course their disease. This group CRC patients, characterized by worst prognosis, has been extensively investigated improve life expectancy. Main efforts, focused on epidermal growth-factor receptor (EGFR), which plays pivotal role in pathogenesis, have led development and introduction clinical practice specific targeted therapies (ie, monoclonal antibodies). Subsequently, scientific community tried identify molecular predictors efficacy such therapies. However, it become clear that EGFR alterations occurring are difficult investigate, therefore predictive is unclear. In contrast, two downstream members (KRAS NRAS) clearly demonstrated. Currently, EGFR- can be administered only wild-type KRAS NRAS genes. Our review addresses medical management metastatic CRC. Specifically, we describe detail biology CRC, focusing signaling pathway, discuss current emerging related biomarkers this field. We also summarize evidence regarding anti-EGFR antibodies examine potential future perspectives.